Meeder Asset Management’s Clearside Biomedical CLSD Stock Holding History

Meeder Asset Management’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-46	Closed	-$1K	–	2151
2019 Q2	$1K	Sell	46 -107	-70%	-$1.91K	﹤0.01%	1935
2019 Q1	$3K	Buy	+153	New	+$3.04K	﹤0.01%	1486
2017 Q2	–	Sell	-9	Closed	-$1K	–	1683
2017 Q1	$1K	Buy	+9	New	+$1.06K	﹤0.01%	1494

Other funds holding CLSD

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Meeder Asset Management's CLSD Position: Q3 2019 in Review

Meeder Asset Management sold out of Clearside Biomedical (CLSD) in Q3 2019, closing a stake of 46 shares — an estimated $1K sold.

Meeder Asset Management first reported a position in CLSD in Q1 2017 and held it in 3 quarters. The position peaked at $3K in Q1 2019. 34 funds tracked by Wall St. Rank hold CLSD as of Q3 2019.

Meeder Asset Management reported no remaining Clearside Biomedical position as of Q3 2019 after selling out during the quarter.
Meeder Asset Management sold 46 Clearside Biomedical shares in Q3 2019, an estimated $1K.
Meeder Asset Management first reported a position in Clearside Biomedical in Q1 2017 and held it in 3 quarters.
Meeder Asset Management's Clearside Biomedical position peaked at $3K in Q1 2019.
34 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2019.

Based on Meeder Asset Management's 13F filing for Q3 2019, filed 17 Oct 2019.